AlphAIAlphAI — Financial news for AI agents
businesstimes.com.sgSEP 152 min read$ABT

Abbott to pay US$385 million in US settlement over contaminated infant formula allegations

Abbott Laboratories will pay $385 million to settle US claims over alleged safety violations at its Michigan plant, which produced contaminated infant formula. The settlement follows a 2022 recall linked to infant illnesses and a nationwide formula shortage. The US Justice Department cited unsanitary conditions and inadequate testing. Abbott denies liability. The funds will go to the government, Medicaid, WIC, and whistleblowers.

Original reporting
businesstimes.com.sg
Published Sep 15, 2026, 4:15 AM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 15, 2026, 4:19 AM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
About AlphAI AI DeskScoring methodologyReport an issue
Abbott to pay US$385 million in US settlement over contaminated infant formula allegations — source image
Source · businesstimes.com.sg
Decision brief

The 30-second read

$ABTBearishMed
01

Why it matters

The settlement underscores regulatory risk in the consumer health space and may trigger broader industry reviews.

02

Market read

The $385 M settlement is a fresh, material legal development for ABT, likely influencing its stock price and sector sentiment.

03

What to watch

Potential for increased demand for competing formula brands and possible regulatory reforms could shift market dynamics.

Relevance 8/10Novelty 8/10Timing: Monday announcement

Background

Abbott's Michigan plant faced contamination issues leading to a recall in 2022 and a nationwide formula shortage.

Company-level read

Ticker impact

$ABTBearishHigh confidence
Context

Abbott Laboratories agreed to pay a $385 million settlement over contaminated infant formula allegations.

Expected impact

Potential near‑term decline of 3‑5% as investors reassess liability exposure.

Evidence & confidence

Large settlement amount, recent recall, and ongoing formula shortage amplify risk perception.

Market effects

Sector

Healthcare and consumer staples sectors may see heightened scrutiny of product safety practices.

Regional

U.S. markets could react with a modest sell‑off in related consumer‑goods stocks.

Global

Limited to markets with exposure to U.S. infant formula supply chain.

Counterpoint

What could challenge this read

If the settlement is fully covered by insurance and the recall resolves supply issues, the stock may rebound quickly.

Key entities

  • Company
    Abbott Laboratories

    U.S. healthcare company producing infant formula.

  • Government Agency
    U.S. Justice Department

    Filed the lawsuit leading to the settlement.

Read at source← All news

Also covered by

2 outlets

Related articles

SEP 15
$ABTHighAI 9/10

Abbott to pay almost $385 million to settle false claims allegation about infant formula

Abbott Laboratories will pay $384.999 million to settle DOJ allegations of false claims related to its 2022 infant formula crisis. The settlement resolves claims about non-compliance with safety requirements at its Sturgis, MI, and Casa Grande, AZ, facilities. The company's recall led to a nationwide formula shortage. The settlement does not determine liability. Abbott's payment includes $348.7 million to the U.S. and $36.3 million to states. The DOJ alleged Abbott knowingly manufactured contami

foodsafetynews.com2 min
SEP 14
$ABTLowAI 8/10

Baby formula maker Abbott Labs agrees to settlement over closure of largest US plant

Abbott Labs will pay $385M to settle legal claims related to a 2022 contamination inquiry at its Sturgis, Michigan plant, which caused a recall and supply shortages. The settlement does not admit fault. Abbott maintains no unopened formula tested positive for Cronobacter. The plant reopened in June 2022 after a closure. The Biden administration took steps to alleviate the shortage.

independent.co.uk2 min